{"article_id": 16, "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/modernas-combination-skin-cancer-therapy-receives-fdas-breakthrough-tag-2023-02-22/", "title": "Moderna's combination skin cancer therapy receives FDA's breakthrough tag", "text": "Feb 22 (Reuters) - Moderna Inc (MRNA.O) said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's (MRK.N) drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.\nShares of Moderna rise 2.5% to $164 after the market.\nThe breakthrough tag is granted by the U.S. Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44% compared with Keytruda alone.\nThe FDA's breakthrough therapy designation is granted to expedite the development and review of drugs that are intended to treat a serious condition.\nThe companies said they plans to initiate a late-stage study in adjuvant treatment of melanoma in 2023.\nReporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli and Shailesh Kuber\nOur Standards: The Thomson Reuters Trust Principles.", "date": "2023-02-22 00:00:00"}